Institution
Menzies Research Institute
About: Menzies Research Institute is a based out in . It is known for research contribution in the topics: Population & Osteoarthritis. The organization has 967 authors who have published 3341 publications receiving 101054 citations.
Topics: Population, Osteoarthritis, Blood pressure, Body mass index, Knee pain
Papers published on a yearly basis
Papers
More filters
••
Jeffrey D. Stanaway1, Ashkan Afshin1, Emmanuela Gakidou1, Stephen S Lim1 +1050 more•Institutions (346)
TL;DR: This study estimated levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs) by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017 and explored the relationship between development and risk exposure.
2,910 citations
••
Royal North Shore Hospital1, University of Queensland2, Charité3, University of Melbourne4, University of Sydney5, University of Western Sydney6, University of Lorraine7, University of Adelaide8, Menzies Research Institute9, Monash University10, Deakin University11, Institute for Health Metrics and Evaluation12, Royal Cornwall Hospital13
TL;DR: In this article, the global burden of hip and knee OA was estimated as part of the Global Burden of Disease 2010 study and the burden of OA compared with other conditions.
Abstract: Objective To estimate the global burden of hip and knee osteoarthritis (OA) as part of the Global Burden of Disease 2010 study and to explore how the burden of hip and knee OA compares with other conditions. Methods Systematic reviews were conducted to source age-specific and sex-specific epidemiological data for hip and knee OA prevalence, incidence and mortality risk. The prevalence and incidence of symptomatic, radiographic and self-reported hip or knee OA were included. Three levels of severity were defined to derive disability weights (DWs) and severity distribution (proportion with mild, moderate and severe OA). The prevalence by country and region was multiplied by the severity distribution and the appropriate disability weight to calculate years of life lived with disability (YLDs). As there are no deaths directly attributed to OA, YLDs equate disability-adjusted life years (DALYs). Results Globally, of the 291 conditions, hip and knee OA was ranked as the 11th highest contributor to global disability and 38th highest in DALYs. The global age-standardised prevalence of knee OA was 3.8% (95% uncertainty interval (UI) 3.6% to 4.1%) and hip OA was 0.85% (95% UI 0.74% to 1.02%), with no discernible change from 1990 to 2010. Prevalence was higher in females than males. YLDs for hip and knee OA increased from 10.5 million in 1990 (0.42% of total DALYs) to 17.1 million in 2010 (0.69% of total DALYs). Conclusions Hip and knee OA is one of the leading causes of global disability. Methodological issues within this study make it highly likely that the real burden of OA has been underestimated. With the aging and increasing obesity of the world9s population, health professions need to prepare for a large increase in the demand for health services to treat hip and knee OA.
2,440 citations
••
Queen Mary University of London1, Winthrop-University Hospital2, Karolinska Institutet3, Boston Children's Hospital4, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico5, Harvard University6, University of Colorado Denver7, McMaster University8, University of Auckland9, Katholieke Universiteit Leuven10, University of Tampere11, University of Birmingham12, Pennsylvania State University13, University of Otago14, QIMR Berghofer Medical Research Institute15, Dartmouth College16, Menzies Research Institute17, Medical University of Łódź18, University of Delhi19, Jikei University School of Medicine20
TL;DR: Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall and patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.
Abstract: Objectives To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and to identify factors modifying this effect. Design Systematic review and meta-analysis of individual participant data (IPD) from randomised controlled trials. Data sources Medline, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, ClinicalTrials.gov, and the International Standard Randomised Controlled Trials Number registry from inception to December 2015. Eligibility criteria for study selection Randomised, double blind, placebo controlled trials of supplementation with vitamin D 3 or vitamin D 2 of any duration were eligible for inclusion if they had been approved by a research ethics committee and if data on incidence of acute respiratory tract infection were collected prospectively and prespecified as an efficacy outcome. Results 25 eligible randomised controlled trials (total 11 321 participants, aged 0 to 95 years) were identified. IPD were obtained for 10 933 (96.6%) participants. Vitamin D supplementation reduced the risk of acute respiratory tract infection among all participants (adjusted odds ratio 0.88, 95% confidence interval 0.81 to 0.96; P for heterogeneity Conclusions Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall. Patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit. Systematic review registration PROSPERO CRD42014013953.
1,431 citations
••
Cleveland Clinic1, MedStar Washington Hospital Center2, University of Texas Health Science Center at Houston3, University of Pennsylvania4, Harvard University5, McMaster University6, McGill University7, University of Padua8, European Institute of Oncology9, University of Chicago10, Oslo University Hospital11, Temple University12, University of Liège13, Memorial Sloan Kettering Cancer Center14, Menzies Research Institute15, Mayo Clinic16
TL;DR: The noninvasive evaluation of LVEF has gained importance, and notwithstanding the limitations of the techniques used for its calculation, has emerged as the most widely used strategy for monitoring the changes in cardiac function, both during and after the administration of potentially car- diotoxic cancer treatment.
Abstract: Cardiac dysfunction resulting from exposure to cancer therapeutics
was first recognized in the 1960s, with the widespread introduction
of anthracyclines into the oncologic therapeutic armamentarium.
Heart failure (HF) associated with anthracyclines was then recognized
as an important side effect. As a result, physicians learned to limit their
doses to avoid cardiac dysfunction. Several strategies have been used
over the past decades to detect it. Two of them evolved over time
to be very useful: endomyocardial biopsies and monitoring of left ven-
tricular (LV) ejection fraction (LVEF) by cardiac imaging. Examination
of endomyocardial biopsies proved to be the most sensitive and spe-
cific parameter for the identification of anthracycline-induced LV
dysfunction and became the gold standard in the 1970s. However,
the interest in endomyocardial biopsy has diminished over time
because of the reduction in the cumulative dosages used to treat ma-
lignancies, the invasive nature of the procedure, and the remarkable
progress made in noninvasive cardiac imaging. The noninvasive
evaluation of LVEF has gained importance, and notwithstanding the
limitations of the techniques used for its calculation, has emerged as
the most widely used strategy for monitoring the changes in cardiac
function, both during and after the administration of potentially car-
diotoxic cancer treatment.
1,316 citations
••
The Catholic University of America1, University of Trieste2, Icahn School of Medicine at Mount Sinai3, GE Healthcare4, Menzies Research Institute5, Siemens6, Hitachi7, Toshiba Medical Systems Corporation8, Philips9, University of Michigan10, University of Massachusetts Medical School11, Cleveland Clinic12, University of Padua13
TL;DR: This technical document is intended to provide definitions, names, abbreviations, formulas, and procedures for calculation of physical quantities derived from speckle tracking echocardiography and thus create a common standard.
Abstract: Recognizing the critical need for standardization in strain imaging, in 2010, the European Association of Echocardiography (now the European Association of Cardiovascular Imaging, EACVI) and the American Society of Echocardiography (ASE) invited technical representatives from all interested vendors to participate in a concerted effort to reduce intervendor variability of strain measurement. As an initial product of the work of the EACVI/ASE/Industry initiative to standardize deformation imaging, we prepared this technical document which is intended to provide definitions, names, abbreviations, formulas, and procedures for calculation of physical quantities derived from speckle tracking echocardiography and thus create a common standard.
1,032 citations
Authors
Showing all 967 results
Name | H-index | Papers | Citations |
---|---|---|---|
Terho Lehtimäki | 142 | 1304 | 106981 |
David Scott | 124 | 1561 | 82554 |
Thomas H. Marwick | 121 | 1063 | 58763 |
John Blangero | 106 | 782 | 51671 |
Jo Salmon | 99 | 445 | 35645 |
Hoda Anton-Culver | 99 | 487 | 39176 |
Zhen Zhou | 96 | 374 | 28536 |
Graeme Jones | 87 | 617 | 28165 |
Flavia M. Cicuttini | 86 | 713 | 34515 |
Kylie Ball | 84 | 395 | 24144 |
Michael J. Quon | 83 | 217 | 29305 |
Terence Dwyer | 78 | 479 | 23543 |
Susan R. Davis | 76 | 412 | 21882 |
Zhongxing Liao | 76 | 422 | 17554 |
Alun D. Hughes | 76 | 578 | 21432 |